GNLX Live signals | Maximize Profits with Getagraph.com

BUY 117418 min ago

@ $8.70

Issued: 13 Feb 2024 @ 09:30

Return: -55.98%

Previous signal: Feb 8 - 14:06

Previous signal: Sell

Return: -7.25 %

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 16:00):

Stats
Today's Volume	123 480
Average Volume	142 170
Market Cap	102.89M
EPS	$-0.253 ( 2024-04-02 )
Next earnings date	( $-0.210 ) 2024-07-05
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.30
ATR14	$0.0250 (0.65%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-29	Szalay Aladar	Sell	6 403	Common Stock
2024-04-30	Szalay Aladar	Sell	20 535	Common Stock
2024-05-01	Szalay Aladar	Sell	33 061	Common Stock
2024-04-22	Szalay Aladar	Sell	14 331	Common Stock
2024-04-23	Szalay Aladar	Sell	22 000	Common Stock

INSIDER POWER
-2.91
Last 100 transactions
Buy: 884 938 \| Sell: 828 182

Volume Correlation

Long: -0.04 (neutral)

Short: 0.10 (neutral)

Signal:(54.611) Neutral

Genelux Corporation Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Genelux Corporation Correlation - Currency/Commodity

-0.80
( strong negative )

-0.44
( neutral )

0.00
( neutral )

-0.43
( neutral )

-0.08
( neutral )

0.65
( weak )

Genelux Corporation Financials

Annual	2023
Revenue:	$170 000
Gross Profit:	$-848 000 (-498.82 %)
EPS:	$-1.160

FY	2023
Revenue:	$170 000
Gross Profit:	$-848 000 (-498.82 %)
EPS:	$-1.160

FY	2022
Revenue:	$11.07M
Gross Profit:	$10.10M (91.25 %)
EPS:	$-0.210

Financial Reports:

No articles found.

Genelux Corporation

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.